Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024

Rhea-AI Summary

Royalty Pharma plc (Nasdaq: RPRX) has announced that it will release its second quarter 2024 financial results on Thursday, August 8, 2024, before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time on the same day to discuss the results.

Investors can access the conference call information and view the live webcast on the 'Investors' page of Royalty Pharma's website. A replay of the conference call and webcast will be available on the company's website for at least 30 days after the event.

NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.

Conference Call Information

Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company's website for at least 30 days.

About Royalty Pharma

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 17 development-stage product candidates. For more information, visit www.royaltypharma.com.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6637
ir@royaltypharma.com

FAQ

When will Royalty Pharma (RPRX) release its Q2 2024 financial results?

Royalty Pharma (RPRX) will release its second quarter 2024 financial results on Thursday, August 8, 2024, before the U.S. financial markets open.

What time is Royalty Pharma's (RPRX) Q2 2024 earnings call scheduled for?

Royalty Pharma's (RPRX) Q2 2024 earnings call is scheduled for 8:00 a.m. Eastern Time on Thursday, August 8, 2024.

Where can I find information about Royalty Pharma's (RPRX) Q2 2024 earnings call?

Information about Royalty Pharma's (RPRX) Q2 2024 earnings call can be found on the 'Investors' page of the company's website at https://www.royaltypharma.com/investors/events/.

How long will the replay of Royalty Pharma's (RPRX) Q2 2024 earnings call be available?

The replay of Royalty Pharma's (RPRX) Q2 2024 earnings call and webcast will be archived on the company's website for at least 30 days after the event.